Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Dose Linearity of New rhPTH(1-84) Formulation in Healthy Volunteers
NCT05137730Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of parathyroid hormone 1-84 in hypoparathyroidism (6 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration, Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity and 2 more. Started Nov 2021; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT05137730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137730.